4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Rosacea by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 31 ongoing clinical trials involving Rosacea
Of the 31 trials,14 trials are in Phase II
Furthermore, 6 trials are in Phase III

Number of ongoing Clinical Trials (for drugs) involving Rosacea by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Rosacea, a dermatology indication. The largest number of ongoing clinical trials for Rosacea is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions engaged in Rosacea-related drug trials.

Rosacea related clinical trial sponsor

Maruho Co Ltd, Alfasigma SpA, Alfasigma SpA, Central South University Xiangya Hospital, Candela Corp and Wake Forest University Health Sciences are among the notable clinical trial sponsors involved in Rosacea. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Rosacea

Ivermectin, Loteprednol etabonate (Lotemax, Loteprol, Alrex), and Doxycycline (Oracea, Efracea, Apprilon) are among the key marketed drugs involving Rosacea.

Ivermectin belongs to macro cyclic lactones known as avermectin. It is formulated as a cream for topical application. Ivermectin exhibits anti-inflammatory properties. Inflammatory mechanisms play an important role in the development of acne inflammatory lesions. The drug candidate by decreasing the cellular and humoral immune responses alleviates the disease progression. Ivermectin is indicated for the treatment of inflammatory lesions of rosacea. Ivermectin was first approved in 2020 and is marketed in the US by Perrigo New York Inc.

Loteprednol etabonate (Lotemax, Loteprol, Alrex), is an anti-inflammatory and anti-allergic agent. It functions via Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1) Agonist mechanism of action. It is formulated as suspension, gel and ointment for ophthalmic route of administration. Loteprednol etabonate is indicated for the treatment of Rosacea and several other indications including Bacterial Conjunctivitis, Ocular Pain (Eye Pain), Keratitis, Allergic Conjunctivitis, Anterior Segment Inflammation, Anterior Uveitis, Giant Papillary Conjunctivitis, Herpes Zoster Ophthalmicus, Iritis, and Ocular Inflammation. Ivermectin was first approved in 1998 and is marketed globally including the US, the UK, Canada, and Germany by several prominent pharma giants including Bausch & Lomb Inc, Dr Gerhard Mann Chem-pharm Fabrik GmbH, and Abic Marketing Ltd.